AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01339559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: Tablet, Flexible dosing up to 200 mg/day, twice daily.~The study will continue until either regulatory approval of brivaracetam has been granted by any Health Authority in an indication of adjunctive treatment of partial onset seizures or until the Sponsor decides to close the study, or until the investigational product development is stopped by the Sponsor.
Study NCT02670642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Proton pump inhibitor
Study NCT02670642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Proton pump inhibitor
Study NCT04195321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: infusion will be started after induction of spinal anesthesia
Study NCT04195321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phenylephrine
Description: infusion will be started after induction of spinal anesthesia
Study NCT01137773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: All patients in the trial will have blood taken hourly for glucose analysis, regardless of their designated group. Adjustments of the insulin dose will be based on measurements of capillary blood glucose level.
Study NCT01137773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional insulin treatment
Description: All patients in the trial will have blood taken hourly for glucose analysis , regardless of their designated group. Adjustments of the insulin dose will be based on measurements of capillary blood glucose level.
Study NCT02325219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 1959 50 mg
Description: Participants will receive subcutaneous injection of CNTO 1959 50 mg.
Study NCT02325219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTNO 1959 100 mg
Description: Participants will receive subcutaneous injection of CNTO 1959 100 mg.
Study NCT02325219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 50 mg
Description: Participants will receive subcutaneous injection of Placebo matched to CNTO 1959 50 mg.
Study NCT02325219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 100 mg
Description: Participants will receive subcutaneous injection of Placebo matched to CNTO 1959 100 mg.
Study NCT01657409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BoNT-A (10 injection)
Description: BoNT-A 100 U 10 injections
Study NCT01657409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BoNT-A (20 injection)
Description: BoNT-A 100 U 20 injections
Study NCT01657409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BoNT-A (40 injection)
Description: BoNT-A 100 U 40 injections
Study NCT01088074 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Histoacryl Tissue Adhesive
Study NCT01088074 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dermabond
Study NCT01088074 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Staples
Study NCT01088074 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monocryl 4-0
Study NCT00817531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: pill form, 100 mg daily
Study NCT02239939 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vest
Description: light weight, adjustable, vest to be worn underneath clothes that weight can be added to
Study NCT02239939 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Participants will undergo a 22 week dietary weight loss intervention which will incorporate dietary practices for achieving weight loss while minimizing muscle and bone loss. Participants will be instructed by the Registered Dietitian to follow a low calorie diet. Individual calorie goals will be adjusted during the study if necessary to achieve a targeted weight loss goal of at least 8%, but no more than 12%, within the intervention time frame.
Study NCT02239939 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Participants will undergo a 22 week dietary weight loss intervention which will incorporate dietary practices for achieving weight loss while minimizing muscle and bone loss. Participants will be instructed by the Registered Dietitian to follow a low calorie diet. Individual calorie goals will be adjusted during the study if necessary to achieve a targeted weight loss goal of at least 8%, but no more than 12%, within the intervention time frame.
Study NCT01210339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel
Study NCT01210339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole/ASA
Description: 20 mg/81 mg once daily for five days (Day 5-9)
Study NCT01870401 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lutonix DCB
Study NCT01870401 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Uncoated PTA Catheter
Study NCT04273178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escalating prophylaxis
Description: For all patients without documented proven or probable invasive fungal disease (IFD), patients will receive fluconazole during the treatment in the laminar air flow units (LAF). After discharged from LAF units, patients will receive anti-mold prophylaxis in case of haplo-identical or HLA-matched unrelated donor transplantation to d+100 without active acute GVHD (aGVHD). In case of active aGVHD, the prophylaxis treatment will be extended until recovery of aGVHD and tapering of immunosuppression. In case of HLA-matched sibling donor, fluconazole will be continued to d+100 and anti-mold prophylaxis will be given in case of active aGVHD.
Study NCT01916265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Study NCT03470493 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ApneaLink Air
Description: ApneaLink Air to be used on each participant undergoing PSG
Study NCT03066427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib 50 mg/d
Study NCT00716105 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard infant formula
Description: From 3 to 12 months of age. As per standard requirement
Study NCT00716105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant formula with different level of proteins
Description: From 3 to 12 months of age. As per standard requirement
Study NCT00452699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
Description: Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
Study NCT00452699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate 250 mcg BID
Description: Fluticasone propionate 250 mcg BID
Study NCT02105454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir (GZR)
Description: 100 mg oral tablet (total daily dose)
Study NCT02105454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir (EBR)
Description: 10 mg oral capsule (total daily dose = 5 capsules)
Study NCT02105454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: 200 mg oral capsule (total daily dose = 4-7 capsules)
Study NCT00648375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propanolol
Description: Participants will take a 40-mg dose of propranolol immediately after they experience a traumatic memory associated with strong hyperarousal symptoms. Participants may take up to two doses a day, if the doses are separated by at least 6 hours.
Study NCT00648375 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take a single dose of placebo immediately after they experience a traumatic memory associated with strong hyperarousal symptoms. Participants may take up to two doses a day, if the doses are separated by at least 6 hours.
Study NCT00648375 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive therapy workbook
Description: Participants will also receive a cognitive behavioral therapy-based workbook in which they will track symptoms and efforts to use cognitive techniques to relieve symptoms each day.
Study NCT00648375 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive therapy workbook
Description: Participants will also receive a cognitive behavioral therapy-based workbook in which they will track symptoms and efforts to use cognitive techniques to relieve symptoms each day.
Study NCT03189446 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Vaginal Cuff Brachytherapy
Description: Within 12 weeks of surgery. Either LDR or HDR brachytherapy will be permitted
Study NCT03189446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin IV on day 1 of a 21 day cycle for 3 cycles
Study NCT03189446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel IV on days 1,8 and 15 of a 21 day cycle for 3 cycles
Study NCT04395794 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2-test
Description: Nasopharyngeal and oropharyngeal testing for SARS-CoV-2
Study NCT04395794 — intervention group
Intervention type: OTHER
Intervention: SARS-CoV-2 questionnaire survey
Description: Questionnaire regarding SARS-CoV-2 symptoms and contact with COVID patients
Study NCT00609479 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteosynthesis
Description: 1. Micronail osteosynthesis. A cast for the first 14 days, thereafter starting physiotherapy. Control at weeks 1,2,5,12.~2. Hoffmann-II-non-bridging osteosynthesis. Removal of device after 5 weeks. physiotherapy starts at 14 days. Control at weeks 1,2,5,12.
Study NCT01707472 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Simtuzumab
Description: 700 mg intravenously for a total of 12 infusions.
Study NCT02217605 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructose
Description: Oral Fructose Challenge (75 g fructose in 500 ml water) following overnight fast
Study NCT02095535 — intervention group
Intervention type: DRUG
Intervention: Chlorhexidine gluconate
Description: antiseptic
Study NCT01412593 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem cell transplant
Description: Patients randomized to the intervention arm will be admitted to the Liver Care Unit. Granulocyte colony-stimulating factor (G-CSF; 300mcg/mL) will be administered for 1 day as a single daily subcutaneous dose. This dose is sufficient to induce 10 folds enrichment for bone marrow cells.
Study NCT00623480 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Description: Prophylaxis treatment includes three times per week administration of 25 IU/kg of Kogenate FS. Dose escalation steps by 5 IU/kg (to 30 IU/kg or 35 IU/kg maximum) exhibiting a bleeding frequency of 12 bleeding episodes per year or greater.
Study NCT00623480 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Description: Treated according to the Kogenate FS package insert indications and study physician recommendations
Study NCT00568646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MKC-1
Description: Oral MKC-1 capsules, administered twice daily, for 14 consecutive days, in a 28-day cycles
Study NCT02665507 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GaAlAs 808nm laser
Description: Hand held superpulsed GaAlAs 808 nm LLLI
Study NCT02665507 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Hand held laser that emits no LLLI
Study NCT01259609 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pars Plana Vitrectomy
Description: 25-gauge three-port pars plana vitrectomy
Study NCT01259609 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pars Plana Vitrectomy
Description: 25-gauge three-port pars plana vitrectomy
Study NCT01330238 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zoledronic acid vs. placebo
Description: Single infusion of zoledronic acid or placebo
Study NCT01330238 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid vs. placebo
Description: Single infusion of zoledronic acid or placebo
Study NCT03801668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-bound Paclitaxel plus S-1
Description: Albumin-bound Paclitaxel 260mg/m2 IV on D1 plus S-1 80mg/m2 PO (Bid) on D1-14 every 21 days.
Study NCT03801668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin plus S-1
Description: Oxaliplatin 130mg/m2 IV on D1 plus S-1 80mg/m2 PO (Bid) on D1-14 every 21 days.
Study NCT02916355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Subjects will receive Anakinra infusion and afterwards they will be fed a very fat containing meal, and postprandial fatigue will be measured regularly until 3,5 hour after the meal.
Study NCT02916355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaCl
Description: subjects will receive NaCl infusion and afterwards they will be fed a very fat containing meal, and postprandial fatigue will be measured regularly until 3,5 hour after the meal.
Study NCT00004262 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT00004262 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Study NCT00004262 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery
Study NCT00004262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: motexafin gadolinium
Description: Given IV
Study NCT00004262 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Description: Undergo MRI with both the clinical 1.5 Tesla and research 8 Tesla magnets
Study NCT00004262 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spectroscopy
Description: Undergo plasma-atomic emission spectroscopy (DCP-AES)
Study NCT02750033 — intervention group
Intervention type: DEVICE
Intervention: Multimodal Spectroscopy (MMS)
Description: surgical margin assessment with multimodal optical spectroscopy (MMS) device
Study NCT02965495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YYD302 2ml
Description: YYD302 2ml
Study NCT02965495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YYD302 3ml
Description: YYD302 3ml
Study NCT02965495 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 3ml
Description: phosphate buffered saline 3ml
Study NCT03124823 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rainbow DCI Sensor
Description: Noninvasive pulse oximeter sensor
Study NCT03776175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05221304 Monotherapy
Description: Participants enrolled in this Arm will receive 15 mg dose of PF-05221304 (3 tablets of 5 mg each) and 3 tablets of Placebo for PF-06865571, each to be taken twice daily for 41 days and once on Day 42.
Study NCT03776175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571 Monotherapy
Description: Participants enrolled in this Arm will receive 300 mg dose of PF-06865571 (3 tablets of 100 mg each) and 3 tablets of Placebo for PF-05221304, all to be taken twice daily for 41 days and once on Day 42.
Study NCT03776175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants enrolled in this Arm will receive 3 tablets for Placebo of PF-05221304 and 3 tablets of Placebo of PF-06865571, to be taken twice daily for 41 days and once on Day 42.
Study NCT03776175 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants enrolled in this Arm will receive 3 tablets for Placebo of PF-05221304 and 3 tablets of Placebo of PF-06865571, to be taken twice daily for 41 days and once on Day 42.
Study NCT03776175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05221304 and PF-06865571 Combination
Description: Participants enrolled in this Arm will receive 15 mg dose of PF-05221304 (3 tablets of 5 mg each) and 3 tablets of PF-06865571 (3 tablets of 100 mg each), each to be taken twice daily for 41 days and once on Day 42.
Study NCT00875745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib-Vorinostat
Description: Patients will be entered in successive cohorts. The first cohort will receive Sorafenib at 400 mg bid (800 mg daily) and Vorinostat at 100 mg bid (200 mg daily).
Study NCT04457427 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NeuRx Diaphragm Pacing System (DPS)
Description: 4 electrodes are implanted into the diaphragm, 2 on each side, during the tracheostomy procedure. The electrodes are connected to the NeuRx external stimulator which will be used to stimulate and monitor diaphragm activity.
Study NCT04457427 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuRx Diaphragm Pacing System (DPS)
Description: 4 electrodes are implanted into the diaphragm, 2 on each side, during the tracheostomy procedure. The electrodes are connected to the NeuRx external stimulator which will be used to stimulate and monitor diaphragm activity.
Study NCT01272999 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Non interventional
Study NCT04464161 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ensure
Description: Ensure protein is a complete nutritional drink with 10g, 240 calories, and 27 vitamins and minerals. It is often used as a nutritional supplementation in many hospitals.
Study NCT04682080 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Needle-free injection
Description: This study was performed among children aged 4-10 years who required dental treatment and were treated at the Department of Pedodontics, Faculty of Dentistry, Gaziosmanpasa University. A total of 120 patients were evaluated in accordance with the exclusion criteria and 94 children (39 girls and 55 boys) were included in this study. Children who needed dental treatment were randomly divided into two groups. All dental injections were administered by the same operator (MB), a pediatric dentist with two years of experience in using the Comfort-In system.~In both groups, the children were asked to rate their pain intensity by choosing the closest statement on the colorful Wong-Baker Pain Scale at four time points: immediately after injection (Pain 1), during treatment (Pain 2), at the end of the treatment (Pain 3) and postoperative first day.Anxiety levels were recorded using the Modified Children's Dental Anxiety Scale face version
Study NCT03464500 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mitopure 500mg
Description: Mitopure containing softgels
Study NCT03464500 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mitopure 1000mg
Description: Mitopure containing softgels
Study NCT03464500 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo containing softgels
Study NCT00646542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Study NCT00646542 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00589446 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hysteroscope
Description: An 8mm hysteroscope with irrigation channel and 30 degree view will be inserted into the uterus prior to curettage in cases of recurrent missed abortion
Study NCT04473456 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Simultaneous EGD and colonoscopy
Description: Patients are examined simultaneously by EGD and colonoscopy
Study NCT03279380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SNP
Description: Screening 150 endurance, 150 power athletes, and 200 healthy control individuals for genetic variant associated to sport performance.
Study NCT03279380 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Interval Training (HIIT)
Description: The subgroup (n = 40) of the athletes will participate in the acute exercises (HIIT Training). In order to investigate the acute effects of the exercise the concentration of circulating myokines will be measured (before, post-exercise and 2 h post-exercise). All participants will visit the laboratory at least three times, scheduled 96 h apart. Exercise will be carried out on the cycling ergometer with simultaneous monitoring of physiological responses. Participants will be asked to follow the prescribed diet regime and not to perform any physical activities / trainings the day before measurements. Baseline measurements will include the V̇o 2 peak test. Then the participants will be randomly divided into two groups. The specific acute exercises will be accomplish in the next two visits.